Payment overview · 2025
General Payments
$332.36
17 reported records · 9 companies
Healthcare provider profile · identity verified
Jason Sargent, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · REEDSPORT, OR · NPI 1972869832
Verified facts
What the public records show
CMS Open Payments records show Jason Sargent, D.O. received $332.36 in general payments during 2025 across 17 reported records.
Edwards Lifesciences Corporation accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $81.08 | 24.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $70.09 | 21.1% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $49.33 | 14.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.37 | 12.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.69 | 6.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.43 | 6.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.70 | 5.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.24 | 4.6% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.43 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $332.36 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $49.33 | 3 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $41.37 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.40 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.40 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.40 | 2 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $33.50 | 1 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $14.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 283 | 87 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 254 | 47 |
| Gabapentin | Gabapentin | 223 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 220 | 57 |
| Losartan Potassium | Losartan Potassium | 196 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 195 | 51 |
| Lisinopril | Lisinopril | 184 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 163 | 45 |
| Omeprazole | Omeprazole | 152 | 49 |
| Trazodone Hcl | Trazodone Hcl | 151 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 150 | 45 |
| Tramadol Hcl | Tramadol Hcl | 146 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 42 |
| Eliquis | Apixaban | 127 | 21 |
| Potassium Chloride | Potassium Chloride | 111 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 31 |
| Carvedilol | Carvedilol | 96 | 23 |
| Ozempic | Semaglutide | 96 | 12 |
| Furosemide | Furosemide | 92 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 92 | 14 |
| Metformin Hcl | Metformin Hcl | 88 | 27 |
| Montelukast Sodium | Montelukast Sodium | 83 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 25 |
| Allopurinol | Allopurinol | 73 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 73 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 70 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 15 |
| Warfarin Sodium | Warfarin Sodium | 65 | 12 |
| Jardiance | Empagliflozin | 64 | 18 |
| Sertraline Hcl | Sertraline Hcl | 64 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 17 |
| Lorazepam | Lorazepam | 52 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 51 | 13 |
| Pregabalin | Pregabalin | 51 | suppressed |
| Meloxicam | Meloxicam | 49 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 13 |
| Celecoxib | Celecoxib | 48 | 13 |
| Clonazepam | Clonazepam | 48 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 48 | 13 |
| Simvastatin | Simvastatin | 48 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 12 |
| Prednisone | Prednisone | 45 | 29 |
| Ventolin Hfa | Albuterol Sulfate | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | 13 |
| Baclofen | Baclofen | 41 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 15 |
| Atenolol | Atenolol | 40 | suppressed |
| Estradiol | Estradiol | 40 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | suppressed |
| Famotidine | Famotidine | 37 | 12 |
| Spironolactone | Spironolactone | 36 | 11 |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 33 | 11 |
| Doxepin Hcl | Doxepin Hcl | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 24 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Methadone Hcl | Methadone Hcl | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Np Thyroid | Thyroid,pork | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 17 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 14 |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sumatriptan | Sumatriptan | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Tudorza Pressair | Aclidinium Bromide | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $332.36 · 17 records | Edwards Lifesciences Corporation | ABRYSVO, Auvelity, CAPLYTA, COMIRNATY, Cologuard Collection Kit, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, LEQVIO, MAVYRET, NURTEC ODT, PAXLOVID, PREVNAR 20, SAPIEN 3 Ultra RESILIA, Veozah, ZAVZPRET, ZENPEP | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error